Review article: maintenance therapy in patients with ulcerative colitis

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• British Society of Gastroenterology guidelines advocate long-term 5-aminosalicylic acid (5-ASA) therapy for ulcerative colitis (UC) remission maintenance.
• Studies indicate increased remission duration with higher 5-ASA maintenance doses (2.4 g/day vs. 1.2 g/day), particularly in extensive UC.
• Retrospective analysis shows lower relapse rates with doses exceeding the median (1.6 g/day).

Purpose of the Study:

• To evaluate the impact of 5-ASA dosage on remission maintenance and relapse frequency in ulcerative colitis.
• To explore the potential role of 5-ASA in reducing colorectal cancer risk in UC patients.
• To inform future clinical guideline revisions regarding optimal 5-ASA dosing for UC.

Main Methods:

• Review of recent studies on 5-ASA maintenance and induction dosages in UC.
• Retrospective analysis comparing relapse rates based on median 5-ASA dose.
• Consideration of emerging evidence on 5-ASA's mechanism of action (PPAR-gamma activation).

Main Results:

• Increasing 5-ASA maintenance dose from 1.2 to 2.4 g/day prolongs remission time, especially in extensive UC.
• Higher 5-ASA doses correlate with lower relapse frequency.
• Continuing induction dosage for 4 extra weeks enhances remission duration and reduces relapse.

Conclusions:

• Current evidence supports higher long-term 5-ASA doses (≥2 g/day) for maintaining UC remission.
• Patient compliance with prescribed 5-ASA regimens is a significant challenge.
• 5-ASA's potential anti-cancer effects warrant further investigation and may influence future treatment recommendations.